Meeting
2020 Genitourinary Cancers Symposium
Prognostic value of novel inflammation index for patients with metastatic castration-resistant prostate cancer.
Authors
Yasutaka Yamada
Department of Urology Graduate School of Medicine, Chiba University, Chiba, Japan
Yasutaka Yamada , Shinichi Sakamoto , Junryo Rii , Satoshi Yamamoto , Shuhei Kamada , Yusuke Imamura , Kazuyoshi Nakamura , Akira Komiya , Hiroomi Nakatsu , Tomohiko Ichikawa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer
Sub Track
Diagnostics
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 212)
Abstract #
212
Poster Bd #
A12
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Predictive and prognostic potential of pretreatment 68Ga-PSMA PET tumor heterogeneity index in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Majid Assadi
Poster
2021 ASCO Annual Meeting
Characteristics of patients (pts) and prognostic factors across treatment lines (TL) in metastatic colorectal cancer (mCRC): An analysis from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.
First Author: Jean-Baptiste Bachet
Poster
2020 Genitourinary Cancers Symposium
Prognostic value of risk stratification using blood biochemical parameters in Japanese patients with metastatic renal cell carcinoma treated by nivolumab.
First Author: Yoshiaki Yamamoto
Poster
2015 Genitourinary Cancers Symposium
Dynamic changes of alkaline phosphatase as surrogate for best clinical benefit and overall survival during very early abiraterone therapy compared to PSA-changes in bone metastatic castration resistant prostate cancer.
First Author: Martin Boegemann